| Brian M Bradley, CRNA | |
|
401 W Pennsylvania Ave, Anaconda, MT 59711 | |
| (406) 563-8528 | |
| (406) 556-3086 |
| Full Name | Brian M Bradley |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 401 W Pennsylvania Ave, Anaconda, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881610616 | NPI | - | NPPES |
| 1881610616 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 27323 (Montana) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | RN27323 (Montana) | Primary |
| Entity Name | Big Horn Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891713533 PECOS PAC ID: 5092612796 Enrollment ID: O20031218000807 |
News Archive
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy - the surgical removal of the prostate - eliminates the pain and discomfort associated with the standard catheter.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company's novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, will be showcasing ARROW Vascular Products along with the newly acquired Vidacare vascular product line at the annual Society of Critical Care Medicine, January 9-13 in San Francisco, California.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 7 days ago
| Entity Name | Butte Pain And Anesthesia Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205869468 PECOS PAC ID: 9133012735 Enrollment ID: O20040206000325 |
News Archive
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy - the surgical removal of the prostate - eliminates the pain and discomfort associated with the standard catheter.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company's novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, will be showcasing ARROW Vascular Products along with the newly acquired Vidacare vascular product line at the annual Society of Critical Care Medicine, January 9-13 in San Francisco, California.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 7 days ago
| Entity Name | St Johns Lutheran Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952312050 PECOS PAC ID: 1557255676 Enrollment ID: O20040210000931 |
News Archive
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy - the surgical removal of the prostate - eliminates the pain and discomfort associated with the standard catheter.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company's novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, will be showcasing ARROW Vascular Products along with the newly acquired Vidacare vascular product line at the annual Society of Critical Care Medicine, January 9-13 in San Francisco, California.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 7 days ago
| Entity Name | Scl Health Medical Group-butte Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477869600 PECOS PAC ID: 2466633102 Enrollment ID: O20110301000023 |
News Archive
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy - the surgical removal of the prostate - eliminates the pain and discomfort associated with the standard catheter.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company's novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, will be showcasing ARROW Vascular Products along with the newly acquired Vidacare vascular product line at the annual Society of Critical Care Medicine, January 9-13 in San Francisco, California.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 7 days ago
| Entity Name | St Johns Lutheran Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1952312050 PECOS PAC ID: 1557255676 Enrollment ID: O20120405000136 |
News Archive
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy - the surgical removal of the prostate - eliminates the pain and discomfort associated with the standard catheter.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company's novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, will be showcasing ARROW Vascular Products along with the newly acquired Vidacare vascular product line at the annual Society of Critical Care Medicine, January 9-13 in San Francisco, California.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian M Bradley, CRNA 401 W Pennsylvania Ave, Anaconda, MT 59711-1999 Ph: (406) 563-8528 | Brian M Bradley, CRNA 401 W Pennsylvania Ave, Anaconda, MT 59711 Ph: (406) 563-8528 |
News Archive
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy - the surgical removal of the prostate - eliminates the pain and discomfort associated with the standard catheter.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company's novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, will be showcasing ARROW Vascular Products along with the newly acquired Vidacare vascular product line at the annual Society of Critical Care Medicine, January 9-13 in San Francisco, California.
Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company's leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 7 days ago